AS-1669058 free base is a GPR119 agonist developed as a potential therapeutic agent for type 2 diabetes; it induces glucose-stimulated insulin secretion both in vitro and in vivo, enhances insulin promoter activity, and improves glucose tolerance and reduces blood glucose levels in db/db mice.